Adjuvant interferon therapy after surgical treatment for hepatitis B/C virus-related hepatocellular carcinoma: A meta-analysis

Hepatology Research

Volumn 44, Issue 2, 2014, Pages 209-217

  Xu, Jian Bo ^a   Qi, Fu Zhen ^a   Xu, Gang ^a   Chen, Guo Feng ^a   Huang, Ming De ^a   Zhang, Jian Huai ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Interferon; Surgery

Indexed keywords

INTERFERON;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER SURGERY; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW;

EID: 84893515060     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12109     Document Type: Article

References (54)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
4. Soerjomataram I, Lortet-Tieulent J, Parkin DM etal. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012; 380: 1840-1850.
5. Kanavos P. The rising burden of cancer in the developing world. Ann Oncol 2006; 17 (Suppl 8): viii15-viii23.
6. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225-235.
7. Rossi L, Zoratto F, Papa A etal. Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol 2010; 2: 348-359.
8. Vitale FV, Romeo P, Vasta F etal. Hepatic intra-arterial interferon alpha 2b-based immunotherapy combined with 5-fluorouracil (5-FU)-based systemic chemotherapy for patients with hepatocellular carcinoma (HCC) not responsive and/or not eligible for conventional treatments: a pilot study. Anticancer Res 2007; 27: 4077-4081.
9. Damdinsuren B, Nagano H, Wada H etal. Interferon alpha receptors are important for antiproliferative effect of interferon-alpha against human hepatocellular carcinoma cells. Hepatol Res 2007; 37: 77-83.
10. Oie S, Ono M, Yano H etal. The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha. Int J Oncol 2006; 29: 1469-1478.
11. Wang L, Wu WZ, Sun HC etal. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg 2003; 7: 587-594.
12. Wada H, Nagano H, Yamamoto H etal. Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. Oncol Rep 2007; 18: 801-809.
13. Noguchi R, Yoshiji H, Ikenaka Y etal. Different tumoricidal effects of interferon subclasses and p53 status on hepatocellular carcinoma development and neovascularization. Int J Oncol 2008; 32: 193-199.
14. Kim BK, Han KH, Ahn SH. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Oncology 2011; 81 (Suppl 1): 41-49.
15. Chen LT, Chen MF, Li LA etal. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg 2012; 255: 8-17.
16. Lo CM, Liu CL, Chan SC etal. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007; 245: 831-842.
17. Sun HC, Tang ZY, Wang L etal. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006; 132: 458-465.
18. Someya T, Ikeda K, Saitoh S etal. Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis. J Gastroenterol 2006; 41: 1206-1213.
19. Ikeda K, Kobayashi M, Seko Y etal. Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: a retrospective study of hepatitis C virus-related liver cancer. Hepatol Res 2010; 40: 1168-1175.
20. Uenishi T, Nishiguchi S, Tanaka S, Yamamoto T, Takemura S, Kubo S. Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol 2008; 98: 358-362.
21. Mazzaferro V, Romito R, Schiavo M etal. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44: 1543-1554.
22. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. QUOROM Group. Br J Surg 2000; 87: 1448-1454.
23. Uenishi T, Nishiguchi S, Tamori A etal. Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. Hepatol Res 2006; 36: 195-200.
24. Kubo S, Nishiguchi S, Hirohashi K etal. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001; 134: 963-967.
25. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002; 89: 418-422.
26. Oon CJ, Chen WN. Lymphoblastoid Alpha-interferon In The Prevention Of Hepatocellular Carcinoma (Hcc) In High-risk Hbsag-positive Resected Cirrhotic Hcc Cases: a 14-Year Follow-up. Cancer Invest 2003; 21: 394-399.
27. Kawano Y, Sasaki A, Kai S etal. Prognosis of patients with intrahepatic recurrence after hepatic resection for hepatocellular carcinoma: a retrospective study. Eur J Surg Oncol 2009; 35: 174-179.
28. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232: 10-24.
29. Blum HE, Spangenberg HC. Hepatocellular carcinoma: an update. Arch Iran Med 2007; 10: 361-371.
30. Abdel-Wahab M, El-Husseiny TS, El Hanafy E, El Shobary M, Hamdy E. Prognostic factors affecting survival and recurrence after hepatic resection for hepatocellular carcinoma in cirrhotic liver. Langenbecks Arch Surg 2010; 395: 625-632.
31. Liu L, Miao R, Yang H etal. Prognostic factors after liver resection for hepatocellular carcinoma: a single-center experience from China. Am J Surg 2012; 203: 741-750.
32. Miao RY, Zhao HT, Yang HU etal. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 2010; 21: 2931-2942.
33. Truong BX, Seo Y, Kato M etal. Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha. Int J Mol Med 2005; 16: 279-284.
34. Liaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 2006; 11: 669-679.
35. Lampertico P, Aghemo A, Viganò M, Colombo M. HBV and HCV therapy. Viruses 2009; 3: 484-509.
36. Bonino F, Marcellin P, Lau GK etal. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 5: 699-705.
37. Feitelson MA, Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett 2007; 18: 157-170.
38. Morise Z, Sugioka A, Mizoguchi Y, Kato R, Tanahashi Y. Stepwise carcinogenesis of hepatocellular carcinoma in a nodule surrounded by hyperplastic and hypervascular liver tissue. Can J Surg 2009; 52: E5-7.
39. Ormeci N. Short- and long-term effects of treatment of chronic hepatitis B and delta virus by IFN. Fundam Clin Pharmacol 2003; 17: 651-658.
40. Nishiguchi S, Shiomi S, Nakatani S etal. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001; 3: 196-197.
41. Murata M, Nabeshima S, Kikuchi K etal. A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine 2006; 33: 121-128.
42. Xu G, Qi FZ, Zhang JH, Cheng GF, Cai Y, Miao Y. Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma. World J Surg Oncol 2012; 10: 163.
43. Li L, Zhang J, Liu X, Li X, Jiao B, Kang T. Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis. J Gastroenterol Hepatol 2012; 27: 51-58.
44. Castells A, Bruix J, Bru C etal. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993; 18: 1121-1126.
45. Sotiropoulos GC, Tagkalos E, Fouzas I etal. Liver transplantation for hepatocellular carcinoma using extended criteria donor grafts. Transplant Proc 2012; 44: 2730-2733.
46. Lee SG, Moon DB. Living donor liver transplantation for hepatocellular carcinoma. Recent Results Cancer Res 2013; 190: 165-179.
47. Turcotte S, Dematteo RP. Resection versus transplantation for early hepatocellular carcinoma: more art than science. Am J Surg 2012; 256: 892-893.
48. Baccarani U, Benzoni E, Adani GL etal. Superiority of transplantation versus resection for the treatment of small hepatocellular carcinoma. Transplant Proc 2007; 39: 1898-1900.
49. Yi NJ, Suh KS, Kim T, Kim J, Shin WY, Lee KU. Current role of surgery in treatment of early stage hepatocellular carcinoma: resection versus liver transplantation. Oncology 2008; 75 (Suppl 1): 124-128.
50. Zhou J, Wang Z, Qiu SJ etal. Surgical treatment for early hepatocellular carcinoma: comparison of resection and liver transplantation. J Cancer Res Clin Oncol 2010; 136: 1453-1460.
51. Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009; 16: 265-271.
52. Poynard T, Munteanu M, Ratziu V etal. Truth survival in clinical research: an evidence-based requiem? Ann Intern Med 2002; 136: 888-895.
53. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
54. Hoshida Y, Shiratori Y, Omata M. Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma. Liver 2002; 22: 479-485.